Patrick Gladding

Summary

Country: New Zealand

Publications

  1. ncbi Late drug-eluting stent thrombosis and erythropoietin: cause and effect?
    P A Gladding
    Auckland City Hospital, Greenlane Cardiovascular Service, Park Rd, Grafton, Auckland, New Zealand
    Heart Lung Circ 16:305-7. 2007
  2. ncbi Images in cardiovascular medicine. Percutaneous closure of a left ventricular free-wall rupture site
    Patrick A Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 113:e748-9. 2006
  3. ncbi Prasugrel, Māori, and personalised medicine in New Zealand
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland 1142, New Zealand
    N Z Med J 123:86-90. 2010
  4. doi The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    JACC Cardiovasc Interv 1:620-7. 2008
  5. doi The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    JACC Cardiovasc Interv 1:612-9. 2008
  6. ncbi Trans fats in New Zealand: time for labelling regulations?
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    N Z Med J 120:U2801. 2007
  7. doi Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    JACC Cardiovasc Interv 2:1095-101. 2009
  8. doi The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation
    Laura Panattoni
    School of Population Health, University of Auckland, Auckland, New Zealand
    Pharmacoeconomics 30:1067-84. 2012
  9. doi Trans-fatty acids in New Zealand patients with coronary artery disease
    Jocelyne R Benatar
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Eur J Cardiovasc Prev Rehabil 18:615-20. 2011
  10. doi Antiplatelet drug nonresponsiveness
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 155:591-9. 2008

Detail Information

Publications14

  1. ncbi Late drug-eluting stent thrombosis and erythropoietin: cause and effect?
    P A Gladding
    Auckland City Hospital, Greenlane Cardiovascular Service, Park Rd, Grafton, Auckland, New Zealand
    Heart Lung Circ 16:305-7. 2007
    ..Two weeks prior to presentation with stent thrombosis the patient had a 50% dose increase of longterm erythropoietin. The prothrombotic effect of erythropoietin may have precipitated the thrombotic event...
  2. ncbi Images in cardiovascular medicine. Percutaneous closure of a left ventricular free-wall rupture site
    Patrick A Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 113:e748-9. 2006
  3. ncbi Prasugrel, Māori, and personalised medicine in New Zealand
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland 1142, New Zealand
    N Z Med J 123:86-90. 2010
    ..A demonstration of the cost-effectiveness of genetic testing, on a population basis, and a proven alternative, personalised strategy is required before the adoption of this technology can be advocated...
  4. doi The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    JACC Cardiovasc Interv 1:620-7. 2008
    ..This study assessed the effect of pharmacogenetics on the antiplatelet effect of clopidogrel...
  5. doi The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    JACC Cardiovasc Interv 1:612-9. 2008
    ..This study evaluated the antiplatelet effect of a higher loading and maintenance dose regimen of clopidogrel and a possible drug interaction with verapamil...
  6. ncbi Trans fats in New Zealand: time for labelling regulations?
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    N Z Med J 120:U2801. 2007
    ..What are trans fats, what harm do they cause, and should New Zealand also consider imposing mandatory regulations on their use in food? This article explores the issues...
  7. doi Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    JACC Cardiovasc Interv 2:1095-101. 2009
    ..Our aim was to assess whether a higher clopidogrel maintenance dose has a greater antiplatelet effect in CYP2C19*2 allele carriers compared with noncarriers...
  8. doi The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation
    Laura Panattoni
    School of Population Health, University of Auckland, Auckland, New Zealand
    Pharmacoeconomics 30:1067-84. 2012
    ..The frequency of the *2 allele varies by ethnicity and the Maoris, Asians and Pacific Islanders of New Zealand have a relatively high incidence...
  9. doi Trans-fatty acids in New Zealand patients with coronary artery disease
    Jocelyne R Benatar
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Eur J Cardiovasc Prev Rehabil 18:615-20. 2011
    ..This observational cross-sectional study in New Zealand patients with surgical coronary artery disease assesses the plasma levels of TFA and the association of TFA levels with clinical markers of vascular disease...
  10. doi Antiplatelet drug nonresponsiveness
    Patrick Gladding
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 155:591-9. 2008
    ..This review article reviews the background, mechanisms, and evidence in support of the clinical significance of this phenomenon...
  11. doi Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results
    John A Ormiston
    Mercy Angiography, Auckland, New Zealand
    JACC Cardiovasc Interv 2:1017-24. 2009
    ..The aim of this study was to determine the safety and efficacy of a novel pimecrolimus-eluting stent in a porcine coronary model and in a phase I clinical trial...
  12. ncbi Education together with a preprinted sticker improves the prescribing of prophylactic enoxaparin
    Patrick Gladding
    Greenlane Cardiovascular Service, Auckland City Hospital, Auckland
    N Z Med J 120:U2461. 2007
    ..Despite this, many patients who would benefit from prophylaxis do not receive this treatment...
  13. ncbi Personalised medicine in New Zealand
    Patrick Gladding
    N Z Med J 121:10-3. 2008
  14. ncbi Clopidogrel and stent thrombosis after percutaneous coronary intervention
    Patrick Gladding
    N Z Med J 120:U2554. 2007